Expertise in
9
conditions

Tim Hassall

South Brisbane, QLD, AU 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
South Brisbane, QLD, AU 
OverviewLocationsClinical Research

Overview

Tim Hassall practices in South Brisbane, Australia. Mr. Hassall is highly rated in 9 conditions, according to our data. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Pineoblastoma, Posterior Fossa Tumor, and Brain Stem Cancer.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

South Brisbane, QLD, Australia
Other Locations
Brisbane, QLD 4101, Australia
Parkville, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: Oral Repotrectinib (TPX-0005)
Study Phase: Phase 1/Phase 2
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine
Study Phase: Phase 2
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
View 2 Less Clinical Trial

27 Total Publications

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Journal: Neuro-oncology
Published: February 22, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hassall's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile